Friday 6 November 2026 Export IMNM’s income statement to Excel — free account

Immunome, Inc.

IMNM Healthcare Biotechnology

Immunome, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $6.9 million, down 23.2% from fiscal 2024.

Revenue: +69.8%
EPS: −30.0%
Free cash flow: −27.0%

Quarter to June 2026, against a year earlier

Insider buying

18.56 0.65 +3.63%

Follow IMNM

Alert me

Market cap: $2.1B
P/E: 0.0×
Fwd P/E: −7.6×
Dividend yield: —
F-score: 4/9
Altman Z: 21.57
Beneish M: n/a
Dividend safety: n/a

Overview

Immunome, Inc. (IMNM) Price to free cash flow

Alert me on Price to free cash flow

Immunome, Inc. has no meaningful price to free cash flow: its trailing twelve-month free cash flow is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 62.1× (June 2023) — the current reading is the lowest in ten years.

Embed this chart

Code for your page

<iframe src="https://stockrow.com/embed/IMNM/price-to-free-cash-flow" width="100%" height="360" style="border:0" loading="lazy" title="Immunome, Inc. price to free cash flow, 10 years"></iframe>
<p style="font-size:12px">Source: <a href="https://stockrow.com/IMNM/metrics/price-to-free-cash-flow">Immunome, Inc. (IMNM) price to free cash flow — stockrow.com</a></p>

Period	Price to free cash flow	Change
FY2025	0.0×	—
FY2024	0.0×	—
FY2023	0.0×	—

Period	Price to free cash flow	Change
Jun 2025	0.0×	—
Mar 2025	0.0×	—
Dec 2024	0.0×	—
Sep 2024	0.0×	—
6 more quarters	Free account

Against its own ten years

Low 0.0× High 62.1×

Ten-year median 0.0×

Current reading's percentile 88

Company	Price to free cash flow
PVLA Palvella Therapeutics, Inc. compare	n/m
BHVN Biohaven Ltd. compare	n/m
LKFT Lakefront Biotherapeutics - Sponsored ADR compare	n/m
VERA Vera Therapeutics, Inc. compare	n/m
CLDX Celldex Therapeutics, Inc. compare	n/m
IMNM Immunome, Inc.	n/m
AUPH Aurinia Pharmaceuticals Inc compare	12.2×
ADMA ADMA Biologics Inc compare	24.5×
VCEL Vericel Corporation compare	45.4×
Biotechnology industry median	24.8×
Healthcare sector median	21.1×
Market median	14.1×

What Price to free cash flow is

Price to Free Cash Flow Ratio shows how much investors pay for each dollar of cash a company generates after its capital spending.

Stock Price ÷ ((Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM)) ÷ (Shares (Basic, Weighted) (latest quarter)))

The full definition of Price to free cash flow →

Immunome, Inc. (IMNM) Price to free cash flow

Price to free cash flow, daily

Annual newest first

Quarterly newest first

Against its own ten years

Price to free cash flow against peers

What Price to free cash flow is

More on IMNM

Price to free cash flow, daily

Annual newest first

Quarterly newest first

Against its own ten years

Price to free cash flow against peers

What Price to free cash flow is

More on IMNM

Stockrow Weekly